每经AI快讯，有投资者在投资者互动平台提问：医未医疗注册资本为112.5985万元人民币，这应该是 2017年成立时注册资本吧，经过2022年C轮融资后注册资本没有变更过吗？ 北陆药业（300016.SZ）8月20日在投资者互动平台表示，医未医疗成立时的注册资本为100万元，目前 的注册资本为112.5985万元人民币。 （文章来源：每日经济新闻） ...

基因测序板块领涨，上涨2.14%，其中透景生命上涨17.78%，益佰制药上涨10.07%，北陆药业上涨 10.02%，南京新百、利欧股份、广生堂涨超9%。（第一财经AI快讯） ...

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

北陆药业回复：感谢您的关注。医未医疗注册资本为112.5985万元人民币，公司目前持有医未医疗 14.9881%的股份，投资金额为3,000万元人民币。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，北陆药业(300016)08月18日在投资者关系平台上答复投资者关心的问题。 投资者提问：请问，参股公司深圳医未医疗科技公司的注册资本多少？员工人数多少？公司参股14％， 资金多少？ ...

来源：金融界 公司回答表示：感谢您的关注。医未医疗注册资本为112.5985万元人民币，公司目前持有医未医疗 14.9881%的股份，投资金额为3,000万元人民币。 金融界8月18日消息，有投资者在互动平台向北陆药业提问：请问，参股公司深圳医未医疗科技公司的 注册资本多少？员工人数多少？公司参股14％，资金多少？ ...

Group 1 - The core viewpoint of the news is that the brain-computer interface concept stocks in the A-share market have shown strong performance, with several companies experiencing significant price increases [1] Group 2 - Company performance highlights include: - Innovation Medical (002173) saw a price increase of 10.00%, with a total market capitalization of 9.995 billion and a year-to-date increase of 184.55% [2] - Pulite (002324) increased by 7.51%, with a market cap of 15.9 billion and a year-to-date increase of 50.88% [2] - Chengyitong (300430) rose by 6.65%, with a market cap of 6.657 billion and a year-to-date increase of 59.67% [2] - Saily Medical (603716) increased by 5.45%, with a market cap of 5.878 billion and a year-to-date increase of 326.18% [2] - Sanbo Brain Science (301293) rose by 3.79%, with a market cap of 12.9 billion and a year-to-date increase of 44.76% [2] - The MACD golden cross signal formation indicates a positive trend for these stocks [1]

Group 1 - The latest stock price of Beilu Pharmaceutical is 9.79 yuan, with a slight increase of 0.01 yuan, representing a 0.10% rise compared to the previous trading day [1] - The stock opened at 9.88 yuan, reached a high of 10.25 yuan, and a low of 9.69 yuan, with a trading volume of 674 million yuan and a fluctuation of 5.73% [1] - Beilu Pharmaceutical primarily engages in chemical pharmaceuticals, with products including contrast agents, hypoglycemic drugs, and anti-anxiety medications [1] Group 2 - The company's subsidiary, Zhejiang Haichang Pharmaceutical, recently received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] - Iopamidol is a low-osmolar, non-ionic water-soluble contrast agent used for CT enhancement imaging and angiography, noted for its lower side effects, making it suitable for patients with renal impairment and high-risk conditions [1] Group 3 - On August 12, the net outflow of main funds was 32 million yuan, with a cumulative net outflow of 85.7 million yuan over the past five days [1]

Group 1: Resumption of Trading - Jin Chengzi plans to acquire 55% stake in Samit and will resume trading tomorrow; Samit specializes in high-precision fast-reflecting mirror business [1] - Quzhou Development intends to purchase 95.4559% of Xian Dao Electronics and will resume trading tomorrow; Xian Dao focuses on the R&D of sputtering targets and evaporation materials for vacuum coating [1] Group 2: Mergers, Acquisitions, and Capital Increases - China Shipbuilding's dissenting shareholders' acquisition request price is set at 30.02 yuan per share [2] - Jiangsu Suopu plans to raise no more than 1.5 billion yuan through a private placement for the ethylene acetate and EVA integration project (Phase I) [3] - Guangli Microelectronics is acquiring 100% of LUCEDA NV to strategically position itself in silicon photonics technology [4] Group 3: Share Buybacks, Increases, and Equity Transfers - Zhenlei Technology has raised its share buyback price from 38.13 yuan per share to 74 yuan per share [5] - Fuanna has conducted its first buyback of 1 million shares [6] - Shaanxi Jinye plans to repurchase shares worth between 40 million and 70 million yuan, with loans not exceeding 63 million yuan [7] - Donghua Energy's controlling shareholder's concerted action party has received a commitment letter for a special loan to increase holdings, not exceeding 225 million yuan [8] - Taimusi's controlling shareholder intends to transfer 29.99% of the company's shares, with Guangzhou State-owned Assets Supervision and Administration Commission becoming the actual controller [9] Group 4: External Investments and Daily Operations - Haikang obtained the clinical trial approval notice for the innovative drug HSK47977 tablets [10] - Rundou Co., Ltd. received approval for the listing application of glucosamine sulfate sodium chloride compound as a chemical raw material drug [11] - Beilu Pharmaceutical's subsidiary Haichang Pharmaceutical's iodine mepivacaine chemical raw material drug has been approved for listing [12] - Baiyun Airport signed a cooperation contract with China Duty Free Group for the operation of the T3 terminal's outbound duty-free project [13] - Guoshield Quantum plans to sign a sales contract worth 76.5418 million yuan with China Telecom Quantum Group for the sale of quantum key distribution hardware and software [14] Group 5: Performance Changes - Zhenlei Technology's net profit for the first half of 2025 is 62.3197 million yuan, a year-on-year increase of 1006.99%; the company continues to strengthen its advantages in special fields such as data links, electronic countermeasures, wireless communication terminals, next-generation radios, and phased array communications, achieving significant growth in orders and projects [15] - Jingchen Co., Ltd. reported a net profit of 497 million yuan for the first half of the year, a year-on-year increase of 37.12% [16] - China Unicom's net profit for the first half of 2025 is 6.349 billion yuan, a year-on-year increase of 5.1% [17] - Shuanghui Development's net profit for the first half of the year is 2.323 billion yuan, a year-on-year increase of 1.17%; the company plans to distribute 6.5 yuan per 10 shares [18] - Jinlongyu's net profit for the first half of the year is 1.756 billion yuan, a year-on-year increase of 60.07% [19]

股票代码：300016 股票简称：北陆药业 公告编号：2025-090 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于"北陆转债"赎回结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、可转换公司债券基本情况 2021年5月6日，公司2021年第三次临时股东大会审议通过了《关于回购注 销部分已获授但尚未解锁的限制性股票的议案》，同意公司回购注销限制性股 票共计1,713,000股。"北陆转债"转股价格由8.80元/股调整为8.81元/股，调整 后的转股价格自2021年6月29日生效。 （一）可转债发行上市概况 经中国证券监督管理委员会证监许可〔2020〕2810号文同意注册，公司于 2020年12月7日向不特定对象发行500万张可转换公司债券，每张面值100元， 发行总额50,000.00万元。 1 经深圳证券交易所同意，公司50,000.00万元可转换公司债券于2020年12月 28日起在深交所挂牌交易，债券简称"北陆转债"，债券代码"123082"。 （二）可转债转股期限 根据《北京北陆药业股份有限公司向不特定对象发 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-091 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于"北陆转债" 摘牌的公告 一、可转换公司债券基本情况 （一）可转债发行上市概况 经中国证券监督管理委员会证监许可〔2020〕2810号文同意注册，公司于 2020年12月7日向不特定对象发行500万张可转换公司债券，每张面值100元， 发行总额50,000.00万元。 经深圳证券交易所同意，公司50,000.00万元可转换公司债券于2020年12月 28日起在深交所挂牌交易，债券简称"北陆转债"，债券代码"123082"。 （二）可转债转股期限 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 根据《北京北陆药业股份有限公司向不特定对象发行可转换公司债券募集 1 1、"北陆转债"赎回日：2025 年 8 月 5 日 2、投资者赎回款到账日：2025 年 8 月 12 日 3、"北陆转债"摘牌日：2025 年 8 月 13 日 4、"北陆转债"摘牌原因：存续期内可转债全部赎回 说明书》（以下简称"《募集说明书 ...